Pfizer: Generalized Anxiety Disorder trials

The registry lists 14 Generalized Anxiety Disorder studies with Pfizer as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 4Phase 2 2Phase 3 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• POC Study in Partially Responsive Generalized Anxiety DisorderTerminatedNCT02310568Phase 2Results posted
• Study Of Remission In Patients Treated For Generalized Anxiety DisorderCompletedNCT01788553
• A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety DisorderCompletedNCT00921063Phase 2
• A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy SubjectsWithdrawnNCT00820794Phase 1
• Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same TimeTerminatedNCT00809536Phase 1
• Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The BodyTerminatedNCT00800280Phase 1
• 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)WithdrawnNCT00738738Phase 3
• A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)TerminatedNCT00735267Phase 3
• Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety DisorderCompletedNCT00715039Not applicable
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)TerminatedNCT00658762Phase 3
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)TerminatedNCT00658372Phase 3
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)TerminatedNCT00658008Phase 3
• A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety DisorderCompletedNCT00542685Phase 3
• An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male VolunteersCompletedNCT00537615Phase 1